Chronic myelomonocytic leukemia
Active Research Protocols
- 01-H-0162 – Ex Vivo Selective Depletion of Alloreactive Donor T-Lymphocytes Using RFT5-SMPT-dgA, a Specific Anti-Interleukin-2 Receptor Immunotoxin: Reducing GVHD Risk Associated with HLA-Matched, Nonmyeloablative, Peripheral Blood Stem Cell Transplantation for Hemat
- 12-H-0146 – Clofarabine Followed by Lenalidomide for Treatment of High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
- 13-C-0132 – Allogeneic Hematopoietic Stem Cell Transplant for Patients with Mutations in GATA2 or the MonoMAC syndrome
NOTE: PDF documents require the freeAdobe Reader.
This page was last updated: January 24, 2014